Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping.

Trial Profile

Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2017

At a glance

  • Drugs Triflusal (Primary) ; Clopidogrel
  • Indications Cardiovascular disorders; Stroke
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms MAESTRO
  • Most Recent Events

    • 24 Feb 2017 Primary endpoint has not been met. (Time to first recurrent stroke) as per results presented at the 42nd International Stroke Conference
    • 24 Feb 2017 Results presented at the 42nd International Stroke Conference
    • 16 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top